GADICKE ANSBERT sold HOWL

Footnotes

Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025.; The shares were sold as follows: 4,702 by MPM Asset Management LLC ("AM LLC"), 29,704 by MPM BioVentures 2014, L.P. ("BV 2014"), 1,981 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 1,022 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 6,541 by MPM Oncology Innovations Fund, L.P. ("MPM OIF") and 24,530 by UBS Oncology Impact Fund L.P. ("UBS Oncology").; The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.075 to $1.188 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.; MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. MPM BioImpact LLC ("BioImpact") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC, a manager of MPM OIF GP and the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.; The shares are held as follows: 400,824 by AM LLC, 2,531,366 by BV 2014, 168,839 by BV 2014(B), 87,127 by AM BV2014, 555,368 by MPM OIF and 2,092,716 by UBS Oncology.